<SEC-DOCUMENT>0001640334-19-000168.txt : 20190206
<SEC-HEADER>0001640334-19-000168.hdr.sgml : 20190206
<ACCEPTANCE-DATETIME>20190206163806
ACCESSION NUMBER:		0001640334-19-000168
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20190201
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190206
DATE AS OF CHANGE:		20190206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inmune Bio, Inc.
		CENTRAL INDEX KEY:			0001711754
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				475205835
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38793
		FILM NUMBER:		19571989

	BUSINESS ADDRESS:	
		STREET 1:		1224 PROSPECT STREET
		STREET 2:		SUITE 150
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		8589643720

	MAIL ADDRESS:	
		STREET 1:		1224 PROSPECT STREET
		STREET 2:		SUITE 150
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>inmune_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html><head><title>inmune_8k.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px"> <table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td> <div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"><font size="2"></font></div> <div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"><font size="2"></font></div></td></tr></table></p> <p style="MARGIN: 0px">&nbsp;&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b><font size="3">UNITED STATES</font></b></p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b><font size="3">SECURITIES AND EXCHANGE COMMISSION</font></b></p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b><font size="3">Washington, D.C. 20549</font></b></p> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b><font size="5">FORM 8-K</font></b></p> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b>CURRENT REPORT</b></p> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center">Date of Report (Date of earliest event reported): <b>February 1, 2019</b></p> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="50%" align="center" border="0"> <tr height="15"> <td style="BORDER-BOTTOM: 1px solid" valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b><font size="5">INMUNE BIO INC.</font></b></p></td></tr> <tr height="15"> <td> <p style="MARGIN: 0px 0px 0px 0in" align="center">(Exact name of registrant as specified in charter)</p></td></tr></table> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="85%" align="center" border="0"> <tr height="15"> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Nevada</b></p></td> <td valign="top" width="5%"> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b>001-38793</b></p></td> <td valign="top" width="5%"> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b>47-5205835</b></p></td></tr> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">(State or other jurisdiction</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">(Commission</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">(IRS Employer</p></td></tr> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">of incorporation)</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">File Number)</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">Identification No.)</p></td></tr></table> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b><u>1224 Prospect Street, Suite 150, La Jolla, CA 92037</u></b></p> <p style="MARGIN: 0px 0px 0px 0in" align="center">(Address of Principal Executive Offices) (Zip Code)</p> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b><u>(858) 964 3720</u></b></p> <p style="MARGIN: 0px 0px 0px 0in" align="center">(Registrant&#8217;s Telephone Number, Including Area Code)</p> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b><u>Not Applicable</u></b></p> <p style="MARGIN: 0px 0px 0px 0in" align="center">(Former Name or Former Address, If Changed Since Last Report)</p> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u>&nbsp;General Instruction A.2. below):</p> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr height="15"> <td width="4%"> <p style="MARGIN: 0px">&nbsp;</p></td> <td valign="top" width="4%"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><font style="FONT-FAMILY: Wingdings">&#168;</font></p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr> <tr height="15"> <td> <p style="MARGIN: 0px">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><font style="FONT-FAMILY: Wingdings">&#168;</font></p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr> <tr height="15"> <td> <p style="MARGIN: 0px">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><font style="FONT-FAMILY: Wingdings">&#168;</font></p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr> <tr height="15"> <td> <p style="MARGIN: 0px">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><font style="FONT-FAMILY: Wingdings">&#168;</font></p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in">Emerging growth company&nbsp;<font style="FONT-FAMILY: Wingdings">x</font></p> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in">If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;<font style="FONT-FAMILY: Wingdings">&#168;</font></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"> <table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td> <div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"></div> <div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"></div></td></tr></table></p> <p style="MARGIN: 0px"> <table class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in"><b>Item 1.01 Entry into a Material Definitive Agreement. </b></p> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px" align="justify">On February 1, 2019, INmune Bio, Inc. (the &#8220;Company&#8221;) entered into subscription agreements for the initial public offing (&#8220;IPO&#8221;) and sold on best efforts basis of 1,020,820 shares of its common stock, par value $.001 per share, at a per share purchase price of $8.00 per share (including subscription agreements with insiders of the Company for an aggregate purchase price of $416,000). In connection with the IPO the Company received gross proceeds of $8,166,560 before deducting placement agent fees and offering expenses. Univest Securities, LLC (&#8220;Univest&#8221;) served as the lead placement agent for the IPO and WallachBeth Capital, LLC and WestPark Capital, Inc. were co-placement agents (Univest, Wallach Beth Capital, LLC and WestPark Capital, Inc. are collectively referred to as the Placement Agents&#8221;). In connection with the IPO, the Company paid the Placement Agents $571,659.20 in commissions and reimbursed Univest for its out-of-pocket expenses. </p> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px" align="justify">The Company also agreed to pay&nbsp;Univest an advisory fee of $30,000&nbsp;upon the closing of the IPO. The fees and expenses paid to the Placement Agents were paid pursuant to the certain Placement Agent Agreement (the &#8220;Placement Agent Agreement&#8221;) between the Company and Univest dated November 16, 2018. </p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;A registration statement relating to the IPO was filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) and was declared effective by the SEC as of December 19, 2018. The offering of the securities was made only by means of a prospectus, forming a part of the registration statement. </p> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px" align="justify">The Company also issued the Placement Agents warrants to purchase&nbsp;40,833 shares of the Company&#8217;s common stock at an exercise price of $9.60 per share, which warrants are exercisable from time to time, in whole or in part, during the five-year period commencing six months from the effective date Effectiveness Date. If there is no effective registration statement registering the shares of Common Stock that the warrants may be exercisable into the warrants on a cashless basis. </p> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in">The foregoing description of the Subscription Agreements, Placement Agent Agreement and Placement Agent Warrants is qualified by its entirety to the Subscription Agreement, Placement Agent Agreement and Placement Agent Warrants filed as exhibits to this Current Report on Form 8-K and incorporated by reference herein. </p> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in"> <table id="pagebreak67a7eb6e-01a5-438c-b214-76e106489f07" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in"><b>Item 7.01 Regulation FD Disclosure</b></p> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px; TEXT-INDENT: 45px">On February 4, 2019, the Company issued a press release announcing the closing of the IPO and announcing that the Company&#8217;s common stock began trading on the Nasdaq Capital Market under the ticker symbol &#8220;INMB&#8221;. A copy of the press release is attached hereto and incorporated herein by reference in its entirety as&nbsp;<u>Exhibit 99.1</u></p> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in"><b>Item 9.01 Financial statements and Exhibits</b></p> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in">(d) Exhibits.</p> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr height="15"> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="9%"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>Exhibit Number</b></p></td> <td valign="top" width="1%"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="90%"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>Description</b></p></td></tr> <tr height="15" bgcolor="#cceeff"> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><a href="http://www.sec.gov/Archives/edgar/data/1711754/000164033418002253/inmune_ex101.htm">1.1</a></p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px"><a href="http://www.sec.gov/Archives/edgar/data/1711754/000164033418002253/inmune_ex101.htm">Form of Subscription Agreement (Incorporated by reference to the Registration Statement on Form S-1 filed by the Company with the Securities and Exchange Commission on November 20, 2018)</a></p></td></tr> <tr height="15" bgcolor="#ffffff"> <td valign="top"> <p style="MARGIN: 0px"><a href="http://www.sec.gov/Archives/edgar/data/1711754/000164033418002253/inmune_ex11.htm">1.2</a></p></td> <td> <p style="MARGIN: 0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px"><a href="http://www.sec.gov/Archives/edgar/data/1711754/000164033418002253/inmune_ex11.htm">Form of Placement Agent Agreement between INmune Bio Inc. and Univest Securities, LLC (Incorporated by reference to the Registration Statement on Form S-1 filed by the Company with the Securities and Exchange Commission on November 20, 2018)</a></p></td></tr> <tr height="15" bgcolor="#cceeff"> <td valign="top"> <p style="MARGIN: 0px"><a href="http://www.sec.gov/Archives/edgar/data/1711754/000164033418002253/inmune_ex42.htm">4.2</a></p></td> <td> <p style="MARGIN: 0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px"><a href="http://www.sec.gov/Archives/edgar/data/1711754/000164033418002253/inmune_ex42.htm">Form of Placement Agent&#8217;s Warrant (Incorporated by reference to the Registration Statement on Form S-1 filed by the Company with the Securities and Exchange Commission on November 20, 2018</a></p></td></tr> <tr height="15" bgcolor="#ffffff"> <td valign="top"> <p style="MARGIN: 0px"><a href="inmune_ex991.htm">99.1</a></p></td> <td> <p style="MARGIN: 0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px"><a href="inmune_ex991.htm">Press release dated February 4, 2019</a></p></td></tr></table> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in"> <table id="pagebreaka9a98529-801f-4a3e-a513-d15222826114" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b>SIGNATURE</b></p> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p> <p style="MARGIN: 0px; TEXT-INDENT: 45px">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p></td> <td valign="top" colspan="2"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>INMUNE BIO INC.</b></p></td> <td></td></tr> <tr height="15"> <td valign="top"></td> <td valign="top" colspan="2"></td> <td> <p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p></td></tr> <tr height="15"> <td valign="top" width="50%"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">Date: February 6, 2019</p></td> <td valign="top" width="3%"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">By:</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="35%"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><i>/s/ David Moss</i></p></td> <td width="12%"></td></tr> <tr height="15"> <td valign="top"></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">David Moss</p></td> <td></td></tr> <tr height="15"> <td valign="top"></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">Chief Financial Officer</p></td> <td></td></tr></table> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr height="15"> <td style="BORDER-BOTTOM: 1px solid"> <p style="MARGIN: 0px 0px 0px 0in" align="center">3</p></td></tr></table> <p style="MARGIN: 0px">&nbsp;</p></BODY><!--Document Created by EDGARMaster--></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>inmune_ex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head><title>inmune_ex991.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="right">&nbsp;<b>EXHIBIT 99.1</b></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><font size="5">INmune Bio Inc. Announces Closing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol &#8220;INMB&#8221;</font></p> <p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="justify">LA JOLLA, CA, Feb. 04, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (&#8220;INmune&#8221; or the &#8220;Company&#8221;), an immunotherapy company focused on developing therapies that harness the patient&#8217;s innate immune system to fight disease, today announced that the Company&#8217;s common stock is expected to commence trading on The Nasdaq Capital Market, on Monday, February 4, 2019 under the ticker symbol &#8220;INMB&#8221;.</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="justify">On February 1, 2019, INmune closed its initial public offering (&#8220;IPO&#8221;) of 1,020,560 shares of its common stock at of $8.00 per share for a total of $8,166,560 in gross proceeds before placement agent fees and offering expenses.</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="justify">Univest Securities, LLC served as the lead placement agent for the IPO. WallachBeth Capital, LLC and WestPark Capital, Inc. were co-placement agents.</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="justify">A registration statement relating to this U.S. offering was filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) and was declared effective by the SEC as of December 19, 2018. The offering of the securities was made only by means of a prospectus, forming a part of the registration statement. Copies of the final prospectus relating to the U.S. offering may be obtained from Univest Securities, LLC. 375 Park Avenue Unit 1502, New York, NY 10152, by telephone at +1 212 343 8888 or email at&nbsp;<u>info@univest.us</u>. In addition, a copy of the prospectus relating to the offering may be obtained via the SEC's website at www.sec.gov.</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="justify">This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>About INmune Bio Inc.</b></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="justify">INmune Bio (NASDAQ: INMB), Inc. is a clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two products platforms that reengineer the patient&#8217;s innate immune system&#8217;s response to their cancer, INKmune and INB03. INKmune is a Natural Killer (NK) cell therapeutic that primes the patient&#8217;s NK cells to attack developing disease. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio&#8217;s product platforms target residual disease and utilize a precision medicine approach for treatment of a wide variety of hematologic malignancies and solid tumors. To learn more, please visit&nbsp;<u>www.inmunebio.com</u>.</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"> <table id="pagebreak248d64d3-bea7-4d9b-8235-443ee315581e" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in"><b>About Univest Securities, LLC.</b></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in">Registered with FINRA since 1993, Univest provides a wide variety of services to our institution/retail clients globally including brokerage and execution services, sales and trading, market making, investment banking and advisory, wealth management. We pride ourselves in providing value-added customer service and building long term mutually benefited relationship with our clients. For more information, please visit:&nbsp;<u>www.univest.us</u>.</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in">Forward-Looking Statements</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in"><i>This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the Company's proposed IPO. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the IPO will be successfully completed. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results.</i></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in"><b>Contact</b></p> <p style="MARGIN: 0px">&nbsp;</p><b>INmune Bio Contact:</b> <p style="MARGIN: 0px">David Moss</p> <p style="MARGIN: 0px">CFO</p> <p style="MARGIN: 0px">(858) 964-3720<br><u>dmoss@inmunebio.com&nbsp; </u></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"><b>Investors:</b></p> <p style="MARGIN: 0px"><b>&nbsp; </b>&nbsp;</p><b>LHA Investor Relations</b> <p style="MARGIN: 0px">Miriam Weber Miller</p> <p style="MARGIN: 0px">Senior Vice President</p> <p style="MARGIN: 0px">(212) 838-3777</p><u>mmiller@lhai.com</u> <b>&nbsp; </b><b>Ascent Investor Relations</b> <p style="MARGIN: 0px">Tina Xiao</p> <p style="MARGIN: 0px">President</p> <p style="MARGIN: 0px">(917) 609-0333</p><u>tina.xiao@ascent-ir.com</u> <p style="MARGIN: 0px">&nbsp; <table class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p></BODY><!--Document Created by EDGARMaster--></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
